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Introduction
Glioblastoma, one of the most malignant tumors in brain, causes progressive neurologic deterioration, a consequent decline in health-related quality of life and, ultimately, death (1, 2) . Under the treatment of multimodality therapies, such as surgical resection, adjuvant radiation, and temozolomide-based chemotherapy, the prognosis of the glioblastoma still remains poor, with the overall survival less than 2 years (3). Thus, research into novel therapeutic strategies for the glioblastoma is urgently required.
One of the most powerful approaches to tumor therapy in recent years, immunotherapy, such as the immune checkpoint inhibitors which aimed to stimulate the hosts' own immune system to eliminate tumor cells and have shown potent efficacy in treating several solid tumors (4) (5) (6) (7) . Emerging results have identified CD47, a transmembrane protein, as a key antiphagocytic molecule that overexpress on most tumor cells and render tumor cells escape from host immune surveillance (8, 9) . Binding of CD47 to signal regulatory protein-α (SIRPα) initiates a signaling cascade that downregulates macrophage phagocytosis (10) . Macrophage phagocytosis depends on the balance of anti-phagocytic signals and pro-phagocytic signals, and CD47 was identified as the primary anti-phagocytic protein (10) (11) (12) . Disrupting CD47/SIRPα axis by anti-CD47 monoclonal antibody or fusion protein has showed a potent inhibition of several solid tumors, including lung cancer, leiomyosarcoma and melanoma (11) (12) (13) . Considering this mechanism and potent preclinical activity, human and murine SIRPα-Fc, CD47-targeting fusion protein, were employed to evaluate the anti-glioblastoma effect by disrupting CD47-SIRPα axis.
Despite recent clinical trials of immunotherapy have demonstrated its potential to control tumors, we still lack detailed understanding of the underlying biology in anti-CD47-induced tumor immune rejection, which can provide novel insights for the improvement of current therapies and for the clinical trial design (14) (15) (16) . Autophagy, a lysosome-dependent recycled process of intracellular components, can be activated by many stimuli, including nutrient deprivation, hypoxia and drug administration (17) . Understanding the role of autophagy in tumor is emerging, and autophagy is known to be involved in tumorigenesis, progression and treatment. Accumulating studies showed that anti-tumor agents, such as asparaginase, arginase and vismodegib, induced cytoprotective autophagy in the tumor cells. Depleting autophagy could increase the antitumor efficacy of these agents (18) (19) (20) . Moreover, phase I clinical trials are ongoing to evaluate the effect of the addition of chloroquine to chemoradiation for glioblastoma (ClinicalTrails. gov Identifier: NCT02378532). Importantly, Soto-Pantoja et al reported that CD47 deficiency or blocking CD47 with antibodies conferred cell and tissue radioprotection via inducing cytoprotective autophagic flux and increased survival of mice exposed to lethal irradiation, indicating that blocking CD47 activated cytoprotective autophagy in normal cells and tissues (21, 22) . Therefore, we hypothesized that autophagy might participate in CD47-targeting glioblastoma immunotherapy and simultaneously disrupting CD47-SIRPα axis and autophagy could be a novel approach for malignant glioblastoma treatment.
In this study, we evaluated the anti-tumor effect of disrupting CD47-SIRPα by SIRPα-Fc in glioblastoma, and then investigated the relationship between CD47/SIRPα and autophagy. Our results showed that SIRPα-Fc activated innate and adaptive immune responses, eliciting potent anti-glioblastoma effect. Meanwhile, autophagy was induced to play cytoprotective roles in glioblastoma cells. Importantly, depletion of the autophagy elicited enhanced anti-glioblastoma efficacy by recruitment of lymphocytes, and activation of apoptosis. In addition, combination of SIRPα-Fc and autophagy inhibitor significantly prolonged the median survival of tumor-bearing mice. Thus, our data elucidated the potent anti-glioblastoma effect of SIRPα-Fc, and highlighted the potential therapeutic strategies for glioblastoma by targeting both CD47-SIRPα axis and autophagy.
Materials and methods

Reagents and antibodies
The reagents and kits were listed as follows: chloroquine and LY294002 (Sigma-Aldrich; St. Louis, MO, USA), Cyto-ID autophagy detection kit (ENZO Life Science; Farmingdale, NY, USA), macrophage colonystimulating factor (Novoprotein; Shanghai, China), LysoTracker and MitoSox™ (Invitrogen; Eugene, OR, USA). Monoclonal antibodies (mAb) against SQSTM1, Phospho-Akt (Ser473), LC3, Phospho-mammalian target of rapamycin (mTOR) (Ser2448) and β-actin were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Horseradish peroxidaseconjugated second antibodies were obtained from MR Biotech (China). Anti-CD4 and anti-CD8 depleting antibodies (clone GK1.5, BP0003-1; clone YTS 169.4, BP0117) were purchased from Bio X Cell (West Lebanon, NH, USA). Human and murine SIRPα-Fc fusion proteins were expressed and purified as described previously (13) . Briefly, the nucleotides encoding the signal peptide were added to human and murine SIRPα-coding sequences, respectively. Then cloning sites were added to the resulting sequences. Furthermore, the sequences were subcloned into the pMac-Fc vector and Chinese Hamster Ovary cells were employed to express SIRPα-Fc.
Cells and culture conditions
Human cell lines, L02, U87 and U251, murine cell lines Ana-1 and GL261, were purchased in 2016, from Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were authenticated under short tandem repeat analysis by the cell bank. Then the cells were expanded and stored in liquid nitrogen upon receipt, and each aliquot was passaged for fewer than 6 months in our laboratory. Glioblastoma cells, U87, U251 and GL261, were cultured in Dulbecco's modified Eagle's medium (Corning; Manassas, VA, USA), and hepatic cells and macrophages were cultured in RPMI-1640 medium (Corning), containing 10% FBS (Capricorn Scientific; Ebsdorfergrund, Germany).
siRNA transfection assay
Non-silencing control siRNA (SCR) (siNO581512211471-10) and human ATG5 (siG10726164423) small-interfering RNA (siRNA) were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). U87 and U251 cells were transfected with siRNA by Lipofectamine™ 2000 Transfection Reagent (Invitrogen, USA).
Phagocytosis assay and lactate dehydrogenase release
Bone marrow-derived macrophages were isolated from 6-week-old male C57BL/6 mice and seeded in plates with Dulbecco's modified Eagle's medium, containing100 ng/ml macrophage colony-stimulating factor and 10% FBS. Seven days later, the adherent cells were collected and identified by flow cytometry under the stain of Alexa Fluor 488 or allophycocyanin allophycocyanin (APC)-conjugated antibodies against CD11b and F4/80 (Biolegend; San Diego, CA, USA). Then, the phagocytosis and lactate dehydrogenase release were detected as described previously (13) .
Confocal microscopy
Glioblastoma cells were treated with SIRPα-Fc and tissues were prepared immediately after mice were sacrificed. Then, cells and tissues were stained with Cyto-ID ® , Hoechst 33342, LysoTracker ® or Mitosox™ as described (18) .
Transmission electron microscopy
Glioblastoma U87 and U251 cells were exposed to SIRPα-Fc for 24 h and tissues were prepared immediately after mice were sacrificed. Then the sliced samples were observed with transmission electron microscope (20) .
Tumor implantation
All procedures involving mice were carried out in accordance with the standards approved by Animal Ethical Committee of School of Pharmacy at Fudan University. To establish subcutaneous glioblastoma xenograft model, 6-week-old BALB/c nude mice were subcutaneously injected with 5 × 10 6 of U87 cells. Intracranial glioblastoma-bearing mice were prepared by intracranial injection with 1 × 10 5 U87 cells. To establish syngeneic immunocompetent glioblastoma models, 6-week-old C57BL/6 mice were subcutaneously injected with 5 × 10 6 of GL261 cells. Three days later, the well-established mice were randomly divided into the indicated groups. Intracranial GL261 glioblastoma-bearing mice were prepared by intracranial injection with 1 × 10 5 GL261 cells. Chloroquine (50 mg/kg) and SIRPα-Fc (10 mg/kg) were intraperitoneally injected once a day and twice a week, respectively. The mice administrated with temozolomide every 2 days
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bone marrow-derived macrophages mTOR mammalian target of rapamycin siRNA small-interfering RNA SIRPα signal regulatory protein α were set as positive controls. The formula (volume = length × width × width/2) was used to calculate the tumor volume. Figure 1A and B). Macrophagesmediated cytotoxicity against U87 cells and U251 cells were measured by lactate dehydrogenase release. The data indicated that SIRPα-Fc alone has negligible cytotoxic effects on glioblastoma cells, while in the presence of macrophages, SIRPα-Fc could remarkably induce cell lysis of U87 and U251 cells (Figure 1A and B; Supplementary Figure 1C is available at Carcinogenesis Online).
Statistical analysis
To verify the pro-phagocytosis effect of SIRPα-Fc, bone marrowderived macrophages were isolated (Supplementary Figure 1D is BABL/c nude mice were employed to establish glioblastoma U87 xenograft models. After SIRPα-Fc treatment for 21 days, tumor weight was shown in (F) and each point indicated an independent value (n = 5) (temozolomide, positive control). *P < 0.05; **P < 0.01.
available at Carcinogenesis Online). When primary macrophages were co-cultured with glioblastoma cells, the average phagocytic index increased from 11.4 to 28.4 and from 10.6 to 28 in SIRPα-Fc-treated U87 and U251 cells, respectively. After SIRPα-Fc treatment, primary macrophages-mediated cytotoxicity against glioblastoma cells were also increased ( Figure 1C and D). Subcutaneous xenograft models were prepared to test the in vivo anti-glioblastoma efficacy of SIRPα-Fc. Tumor-bearing mice were randomly divided into four groups, isotype control, SIRPα-Fc, vehicle control and temozolomide-positive control. Significant difference in the mean tumor volume was observed from 7 days after SIRPα-Fc treatment and persisted through the remaining experiment ( Figure 1E ). After 21 days' treatment with SIRPα-Fc, the mean tumor weight of the cohort treated with SIRPα-Fc was 458 ± 159.59 mg versus 1452 ± 303.10 mg of the isotype control cohort (P < 0.01) ( Figure 1F ).
These data revealed that disrupting CD47-SIRPα axis by SIRPα-Fc elicited potent macrophage-mediated anti-glioblastoma effect.
SIRPα-Fc-triggered autophagy and autophagic flux in glioblastoma cells in vitro and in vivo
Autophagy is a complex process, including three main stages, autophagosomes formation, autophagosomes and lysosomes fusion, and clearance of autophagosomes in lysosomes (17) . Transmission electron microscope was employed to observe the formulation of autophagosomes, which were characterized by double membranes. After glioblastoma cells being exposed to SIRPα-Fc for 24 h, more double-membrane autophagosomes were observed when compared with vehicle controls (Figure 2A ; Supplementary Figure 2A is available at Carcinogenesis Online). To test autophagy induction, the level of SQSTM1 and LC3, two autophagy-related proteins, were examined. Figure 2B presented a time-dependent decrease of SQSTM1 while increase of LC3-II in SIRPα-Fc-treated U87 and U251 cells. Cyto-ID green, a specific dye for autophagosomes, was applied to confirm the onset of autophagy. Similar to the positive control, SIRPα-Fctreated cells showed an increased punctate fluorescence, which localized in the cytoplasm (Supplementary Figure 2B is available at Carcinogenesis Online).
Actually, accumulation of autophagosomes and LC3-II only represent the activation of autophagy, not the completion of entire autophagy pathway. LysoTracker red, a lysosome specific dye, was combined with Cyto-ID green to detect the entire autophagic flux. We found that formation of autophagosomes with green fluorescence at 12 h, accumulated to the extreme and then fused to lysosomes at 24 h, finally clearance of autophagosomes in lysosomes at 48 h in SIRPα-Fc-treated glioblastoma cells ( Figure 2C ). In addition, chloroquine, an autophagy inhibitor that results in LC3-II accumulation through preventing fusion of autophagosome with lysosome, was employed to confirm the autophagic flux. As shown in Supplementary Figure 2C and D is available at Carcinogenesis Online, SIRPα-Fc induced a timedependent LC3-II accumulation, while in combination with chloroquine further enhanced SIRPα-Fc induced LC3-II accumulation.
To further detect whether autophagy was activated by SIRPα-Fc in vivo, ultrastructural analysis and immunoblotting were used to examine the autophagy levels in glioblastoma U87 xenograft tumors. Figure 2D and E showed that targeting CD47 by SIRPα-Fc increased autophagosomes accumulation and upregulated LC3-II expression in glioblastoma cells in vivo.
Taken together, targeting CD47 by SIRPα-Fc-triggered autophagy and autophagic flux in glioblastoma cells in vitro and in vivo.
Depleting autophagy potentiated SIRPα-Fc-triggered phagocytosis and cytotoxicity of macrophage against glioblastoma cells
To evaluate the role of autophagy in CD47-targeting treatment in glioblastoma, autophagy inhibitors and siRNA were used to inhibit SIRPα-Fc-induced autophagy. SIRPα-Fc-induced autophagy could be successfully inhibited by chloroquine and LY294002 (a lysosome inhibitor and a phosphatidylinositol-3-kinase inhibitor), respectively ( Figure 3A) . Compared with vehicle control, chloroquine or LY294002 alone had negligible direct effects on the phagocytosis and cytotoxicity. When compared with SIRPα-Fc alone, SIRPα-Fc combined with chloroquine significantly potentiated macrophage-induced cytotoxicity and phagocytosis against U87 cells ( Figure 3B ). In addition, bone marrow-derived macrophages were also used to certify the crucial role of autophagy. Depleting autophagy by chloroquine and LY294002 also heightened SIRPα-Fc-triggered phagocytosis and cytotoxicity of primary macrophages ( Figure 3C ). Furthermore, to verify the critical role of autophagy in SIRPα-Fc-triggered macrophages phagocytic and cytotoxic activities, ATG5, one key molecular in autophagy induction, was knocked down in glioblastoma cells. As shown in Figure 3D and E, siRNA-ATG5 selectively decreased ATG5 protein expression when compared with siRNA-SCR, the non-silencing scrambled control. After knockdown of ATG5 in SIRPα-Fc-treated glioblastoma cells, the phagocytosis and cytotoxicity of macrophages were also enhanced. In summary, these results demonstrated that depletion of autophagy by autophagy inhibitors or siRNA increased SIRPα-Fc-triggered macrophage-mediated antiglioblastoma effects in vitro.
Inhibition of autophagy enhanced the antiglioblastoma effect of SIRPα-Fc and prolonged the median survival of SIRPα-Fc-treated mice Next, we focused on evaluating the therapeutic effect of simultaneously disrupting CD47/SIRPα axis and autophagy for glioblastoma treatment. In subcutaneous glioblastoma models, the tumor volume showed no significant difference between chloroquine-treated cohort and vehicle control. However, the mean tumor volume reduced significantly from day 11 till the remaining experiment in SIRPα-Fc and chloroquine co-treatment cohort (P < 0.01) ( Figure 4A ). After 21 days' treatment, mice were sacrificed and xenograft tumors were resected ( Figure 4B ). Mean tumor weight of the cohort co-treated with SIRPα-Fc and chloroquine was 136 ± 78.93 mg versus 514 ± 127.79 mg of the cohort treated with SIRPα-Fc alone (P < 0.01) ( Figure 4C ). Then, we assessed whether blocking CD47/SIRPα axis and autophagy could improve the survival of mice bearing intracranial U87 glioblastoma. Compared with the vehicle control, a median survival of 23 days, chloroquine alone had no obvious effects on the survival, whereas mice treated with SIRPα-Fc had a median survival of 38 days, mice co-treated with SIRPα-Fc and chloroquine had a significantly extended median survival of 49 days. Besides, the median survival of cohort administrated with temozolomide, temozolomide plus chloroquine were 53 and 59 days, respectively. Mice co-administrated with temozolomide, chloroquine and SIRPα-Fc have median survival over 80 days ( Figure 4D ).
These data showed that SIRPα-Fc showed potent anti-tumor effect, and targeting both CD47-SIRPα and autophagy could elicit enhanced anti-glioblastoma effect and significantly prolong the median survival.
Blocking autophagy enhanced CD47-SIRPα disrupting-induced macrophages infiltration and glioblastoma cells apoptosis
Autophagy-related pathway and the crucial members were investigated to explore the potential mechanism of SIRPα-Fctriggered autophagy. Our data showed that targeting CD47 by SIRPα-Fc suppressed Akt/mTOR pathway, a major regulator of autophagy, via downregulation of phosphorylated Akt/mTOR in a time-dependent manner in vitro ( Figure 5A ). To validate it, we detected the level of phosphorylated Akt and mTOR in SIRPα-Fctreated glioblastoma tumors and found that SIRPα-Fc inactivated Akt/mTOR pathway in vivo ( Figure 5B ). Meanwhile, hematoxylin and eosin staining showed that simultaneously blocking CD47 and autophagy elicited increased tumor cell necrosis ( Figure 5C ). CD68 (specific marker of macrophage) was employed to access macrophages infiltration in the tumor microenvironment and SIRPα-Fc (10 mg/kg) bytransmission electron microscope, arrows point to autophagosomes. (E) Western blot assay was used to examine LC3-II levels in glioblastoma xenograft tumors. Image J was used to quantify the densitometric values and the value of control was set to 1.0. These results were shown as means ± standard deviations from three independent experiments (β-actin, a loading control). **P < 0.01.
we found that treatment with chloroquine further increased SIRPα-Fc-induced macrophages infiltration in the xenograft tumors ( Figure 5D ). To access whether apoptosis was involved in the anti-glioblastoma effect of blocking both CD47/SIRPα and autophagy, the level of Caspase 9/3 and PARP, three key regulators of apoptosis, were detected. Figure 5E showed that blocking autophagy increased SIRPα-Fc-activated cleavage of PARP, Caspase 9/3 in the glioblastoma xenograft tumors, indicating that apoptosis was further increased.
In brief, inactivation of Akt/mTOR was involved in SIRPα-Fc-triggered autophagy. Depleting autophagy could further enhance CD47-SIRPα disrupting-induced infiltration of macrophages and apoptosis of glioblastoma cells, eliciting reinforced anti-glioblastoma effect. release were shown as means ± standard deviations from five independent experiments. Macrophages in B and C were Ana-1 and bone marrow-derived macrophage cells, respectively. (D and E) Glioblastoma U87 and U251 cells were transfected with ATG5 siRNAs, and ATG5 expression were detected. Phagocytic index and LDH release were presented as described in B and C. ImageJ was used to quantify the densitometric values and the value of control was set to 1.0. These results were shown as means ± standard deviations from three independent experiments (β-actin, a loading control). **P < 0.01; NS, no significance.
Adaptive immune response was involved in the anti-glioblastoma effects of disrupting CD47/SIRPα and autophagy
In addition to the role as primary effector in innate immune response, macrophages have been shown to play an early role in adaptive immune response (23) . To evaluate whether adaptive immune response was involved in SIRPα-Fc-triggered glioblastoma rejection, we first detected the anti-tumor effect of murine SIRPα-Fc in vitro and found that murine SIRPα-Fc increased macrophages-mediated phagocytosis and cytotoxicity against GL261 cells ( Figure 6A ). Then syngeneic immunocompetent glioblastoma models were established. After murine SIRPα-Fc administration, the number of tumor-infiltrating CD4 + and CD8 + T cells increased from 6.23% to 16.9% and from 24.7% to 40.6%, respectively ( Figure 6B ). To access which T-cell subset was participated in blocking CD47-mediated anti-glioblastoma efficacy, anti-CD4 and anti-CD8 mAb were used to deplete CD4+ and CD8+ T cells, respectively. As shown in Figure 6C , compared with the SIRPα-Fc cohort, depleting CD4 + T cells showed no significant effects on the tumor volume. While absence of CD8 + T cells, a difference could be observed from day 7 to the residual experiment (P < 0.01 versus murine SIRPα-Fc). At day 21, mice were sacrificed and the tumors were resected (Supplementary Figure 3 is available at Carcinogenesis Online). Mean tumor weight of the cohort IgG1-Fc, murine SIRPα-Fc, murine SIRPα-Fc plus anti-CD4 mAb, and murine SIRPα-Fc plus anti-CD8 mAb was 1382 ± 235.78 mg, 338 ± 114.32 mg, 384 ± 117.60 mg and 676 ± 117.43 mg ( Figure 6C ). Subsequently, we validated the synergistic anti-glioblastoma effect of murine SIRPα-Fc and chloroquine. SIRPα-Fc combined with chloroquine significantly increased phagocytosis and cytotoxicity of macrophage against GL261 cells when compared with SIRPα-Fc alone in vitro ( Figure 6D ). In immunocompetent glioblastoma models, at day 21, the mean tumor weight of the group treated with IgG1-Fc, chloroquine, murine SIRPα-Fc and murine SIRPα-Fc plus chloroquine, temozolomide, temozolomide plus chloroquine, temozolomide plus SIRPα-Fc plus chloroquine were 1221 ± 202.90 mg, 1164 ± 214.55 mg, 436 ± 93.17 mg, 146 ± 28.81 mg, 132 ± 35.64 mg, 56 ± 40.99 mg and 8 ± 10.95 mg, respectively, which showed that combination use of chloroquine also reinforced the antiglioblastoma efficacy of disrupting CD47/SIRPα in immunocompetent glioblastoma models ( Figure 6E; Supplementary Figure 4 is available at Carcinogenesis Online). During the treatment, no apparent body weight loss was observed, which indicated that blocking CD47/SIRPα axis and autophagy might be safe in vivo (Supplementary Figure 5 is available at Carcinogenesis Online). Intracranial xenograft models were well-established to assess the effect of SIRPα-Fc and chloroquine on the survival (n = 5 per group). The tumor-bearing mice treated with temozolomide served as positive control. **P < 0.01; NS, no significance.
Furthermore, we assessed whether blocking CD47/SIRPα axis and autophagy could improve the survival of mice bearing intracranial GL261 glioblastoma. Compared with the IgG1-Fc control, a median survival of 20 days, chloroquine alone had no obvious effects on the survival, whereas mice treated with murine SIRPα-Fc had a median survival of 35 days, mice co-treated with murine SIRPα-Fc and chloroquine had an extended median survival of 58 days. Besides, mice administrated with temozolomide, temozolomide plus chloroquine had median survival of 56 and 67 days, respectively, and the median survival of cohort treated with temozolomide plus chloroquine plus murine SIRPα-Fc was more than 80 days ( Figure 6F ).
These data indicated that adaptive immune response, including CD8 + T-cell subsets, were beneficial to the anti-glioblastoma effect of disrupting CD47-SIRPα and autophagy, and significantly prolonged survival in immunocompetent glioblastoma models.
Discussion
Despite therapies for glioblastoma advances over the past years, the overall survival period still lacks substantial improvement, leading to the investigation of new treatment options targeting specific immune checkpoints (24) . CD47, an integrin-associated protein, overexpressed on most tumor cells and has been considered as a novel immune checkpoint molecule. Through CD47 binding to SIRPα, tumor cells transmit "don't eat me" signals to macrophages (6) . On the basis of this mechanism, CD47-SIRPα axis targeting therapeutic approaches have been generated and showed the potential to treat hematologic malignancies and several solid tumors (25) (26) (27) . Among the multiple approaches, CD47-targeted mAb, including Bric126 and B6H12, showed the potent anti-tumor efficacy in leukemia, colon cancer and nonsmall cell lung cancer (11, 27) . In this study, we first revealed that disrupting CD47/SIRPα axis by SIRPα-Fc fusion protein triggered macrophage-triggered phagocytosis and cytotoxicity and then elicited potent anti-glioblastoma efficacy.
Therapeutic approaches, such as anti-CTLA-4 and anti-PD-1/PD-L1, have previously been investigated for glioblastoma (28, 29) . In this study, results showed that SIRPα-based fusion protein could elicit potent effect against glioblastoma in subcutaneous xenograft models. Due to the presence of blood-brain barrier, brain tumors are challenges for the immune checkpoint inhibitors (30) (31) (32) (33) (34) . Emerging evidence demonstrated that central nervous system can interact with systemic immune system, indicating that central nervous system is immunocompetent (32, 35) . Our investigation showed that, in the intracranial glioblastoma xenograft model, SIRPα-Fc extended the median survival of glioblastoma-bearing mice. In the immunocompetent subcutaneous allograft models and intracranial allograft models, the results also showed that blockade of CD47/SIRPα to detect the level of cleaved-PARP and cleaved-Caspase 9/3. Image J software was employed to quantify the densitometric values and the value of control was set to 1.0. These results were shown from three independent experiments (β-actin, a loading control). *P < 0.05; **P < 0.01.
by murine SIRPα-Fc triggered significant anti-glioblastoma efficacy. A recent study showed that blocking CD47 by Hu5F9-G4, an anti-CD47 antibody, was an efficacious approach for multiple pediatric brain malignancies (10) . CD47-blocking immunotherapy was also reported to promote an inflammatory response and further prolong the survival of surgical resection in glioblastoma multiforme xenograft model (36) . Thus, these results indicated that CD47-targeting immunotherapy could be a viable option for the therapy of glioblastoma.
Although disrupting CD47/SIRPα interaction showed the potential as a validated target for cancer therapy, to some tumors, blocking CD47 could not eliminate the tumors cells completely (11) . During the process of CD47-targeted immunotherapy, multiple therapy resistances emergeed in the tumors (8, 37) . Mechanisms of the resistance depended on the tumor size, tumor microenvironment and target expression. On the basis of these mechanisms, various efforts have been made to further enhance the anti-tumor efficacy (37) (38) (39) (40) . Previous studies reported that suppression of CD47 increased radioresistance in vitro and in vivo via activation of cytoprotective autophagy, and inhibiting autophagy sensitized cells to ionizing radiation (21, 22) . In this study, we first found that SIRPα-Fc could transport through blood-brain barrier to disrupt CD47-SIRPα axis, trigger autophagy and autophagic flux via inactivation of Akt/mTOR pathway in glioblastoma cells. Inhibiting autophagy by pharmacological inhibitors and siRNA further potentiated SIRPα-Fc-triggered macrophage phagocytosis and cytotoxicity. To explore potent anti-glioblastoma efficacy, various efforts have been paid. Kanzawa et al. reported that autophagy was involved in temozolomide-induced cytotoxicity of malignant glioma and blocking autophagy by chloroquine enhanced temozolomide-induced cytotoxicity (41, 42) . Subsequently, the results of phase I/II trial (ClinicalTrials.gov, NCT00224978) showed that combination with chloroquine and conventional therapies, including resection, temozolomide and radiotherapy, further extended the median survival time in newly diagnosed glioblastoma multiforme patients (43) . Data from another phase I/II clinical trial (ClinicalTrials.gov, NCT00486603) exhibited that inhibiting autophagy by hydroxychloroquine could not further improve the overall survival in newly diagnosed glioblastoma multiforme patients under the treatment with temozolomide and radiation therapy (44) . The difference might be caused by the complex internal environment and dose-limiting toxicity, indicating that the development of lower-toxicity and high-efficient compounds to inhibit autophagy was still needed. Our results demonstrated that inhibiting autophagy by chloroquine significantly potentiated the anti-glioblastoma efficacy of SIRPα-Fc in subcutaneous xenograft and allograft models, and extended the median survival in the intracranial glioblastoma xenograft and allograft models, indicating that targeting CD47/ SIRPα axis combined with autophagy depletion could be a promising and potential approach for glioblastoma therapy.
CD47/SIRPα is an immune checkpoint in activation of systemic immune system via regulating macrophages phagocytosis and antigen uptake, promoting antigen presentation to T cells (45) (46) (47) . Previous studies showed that T-cell subsets were essential for anti-CD47 antibodies-mediated tumor rejection (23, 48) . Recently, new data from TTI-621 (a CD47-blocking fusion protein developed by Trillium therapeutics Inc.) suggested that blocking CD47 was able to stimulate both innate and adaptive immune responses in lymphoma xenograft and syngeneic models, and repeated dosing of TTI-621 could maintain clinically acceptable platelet levels (49, 50) . In addition, clinical phase I trials are currently ongoing to evaluate the effect of TTI-621 in patients with solid tumors (NCT02890368) and hematologic malignancies (NCT02663518). Consistent with the previous studies, our results indicated that blocking CD47/SIRPα could increase CD8 + T cells in immunocompetent glioblastoma allograft models. Through administration of SIRPα-Fc with CD8 + T-cell depleting mAb, our data indicated that CD8 + T-cell subset played a key role in CD47/SIRPα blockade-mediated glioblastoma regression.
Combination of SIRPα-Fc-mediated CD47/SIRPα blockade and autophagy depletion may provide several clinical implications. First, SIRPα-Fc fusion protein-based immunotherapy could be a viable option for glioblastoma. Second, combined with autophagy depletion could be a promising and potential approach to potentiate the anti-glioblastoma effect of disrupting CD47/SIRPα axis. Third, patients receiving SIRPα-Fc fusion protein-based immunotherapy could benefit from both innate and adaptive responses against glioblastoma.
In summary, this study first showed that SIRPα-Fc, novel CD47-blocking fusion protein, showed potent anti-tumor effect in glioblastoma via increasing macrophages cytotoxicity and phagocytosis against glioblastoma cells. During the treatment, cytoprotective autophagy was activated in glioblastoma cells. Combination of CD47-SIRPα blockade and autophagy depletion elicited enhanced anti-glioblastoma efficacy and prolonged the survival. In addition, in immunocompetent glioblastoma allograft models, adaptive immune response, including CD8 + T-cell subsets, was involved in SIRPα-Fc-elicited anti-glioblastoma effect. Figure 6G showed that targeting both CD47 and autophagy elicited synergetic anti-glioblastoma effect, demonstrating that blockade of CD47-SIRPα axis and autophagy might be a novel therapeutic approach for glioblastoma. Supplementary Figures 1-5 can be found at Carcinogenesis online.
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